For the eighth year, Med Ad News has chosen three Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
The debate in Washington over drug pricing is getting louder and nastier, and drug marketing is getting caught in the crossfire.
With presidential primaries right around the corner, the cost of prescription drugs is at the top of the public’s healthcare priority list for the President and Congress, according to polling data from the Kaiser Family Foundation.
Ogilvy CommonHealth Worldwide is introducing a new service offering to its family, Wellbeing@OgilvyCommonHealth, to focus on the health and wellness needs of the American healthcare consumer.
Many a blog, article, and cover story has focused on the impact (current and future) of healthcare reform. But some interesting healthcare industry changes have been occurring simultaneously with, and are very much accelerated by, the impact of reform. One of these important market changes is the shift from traditional silos of key customer decision-making to a more blended approach to healthcare (and formulary) decision-making.
After five years of failed attempts, U.S. Senate Republicans on Thursday passed a symbolic partisan bill to gut President Barack Obama’s signature healthcare reform law, but the effort has already been condemned to death by Obama’s plans to veto it. The Republican-controlled Senate voted 52-47 to repeal several core Obamacare provisions under special budget […]
The Global Awards for the World’s Best Healthcare & Wellness Advertising Announces 2015 Award Winners
McCann Health is Agency Network of the Year, Langland Awarded Global Healthcare Agency of the Year, Grand Global Goes to Downtown Partners New York, NY – December 3, 2015: The Global Awards℠, for the World’s Best Healthcare & Wellness Advertising℠ announced the 2015 award winners today at ceremonies taking place at New York Academy […]
Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. Drug prices are set to be a major issue in the run-up to the U.S. presidential election next year, with Democratic candidate Hillary […]
(Reuters Health) – U.S. public health funding – which covers things like disease prevention, cancer screenings, contraceptives and vaccines – has been steadily falling in recent years and is expected to keep going down, a recent study projects. Real, inflation-adjusted public health expenditures surged from $39 per capita in 1960 to $281 per capita in […]
Dublin-based Shire (SHPG) announced today that it will acquire Burlington, Mass.-based Dyax Corporation (DYAX) for about $5.9 billion. Shire will pay $37.30 per Dyax share in cash, totaling around $5.9 billion. In addition, if Dyax’s pipeline product, DX-2930 for the treatment of HAE, a rare, debilitating genetic inflammatory condition, is approved, Dyax shareholders will receive […]